Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Asset disposition
Acq. announced
Director departure
CC transcript
Inv. presentation
Jazz Pharmaceuticals plc (JAZZ) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2023 8-K Quarterly results
Docs: "Jazz Pharmaceuticals Announces Second Quarter 2023 Financial Results and Raises 2023 Full Year Financial Guidance – Strong execution delivered second quarter 2023 total revenues of $957 million –"
05/10/2023 8-K Quarterly results
Docs: "Jazz Pharmaceuticals Announces First Quarter 2023 Financial Results and Affirms 2023 Financial Guidance Focus on commercial execution drove 1Q23 total revenues of $892.8 million"
03/01/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2022 Financial Results and Provides 2023 Financial Guidance Strong Execution Drove Record Revenues in 2022 of $3.7 billion, an increase of 18% over 2021"
01/09/2023 8-K Investor presentation
Docs: "Presentation slides by Jazz Pharmaceuticals plc on January 9, 2023",
"Presentation slides by Jazz Pharmaceuticals plc on January 9, 2023"
01/04/2023 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
12/21/2022 8-K Quarterly results
12/05/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
11/09/2022 8-K Quarterly results
10/19/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance"
05/04/2022 8-K Quarterly results
05/04/2022 8-K Quarterly results
04/07/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE ™ Molecule"
03/28/2022 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Jazz Pharmaceuticals Announces Agreement to Divest Sunosi ® to Axsome Therapeutics"
03/01/2022 8-K Quarterly results
01/10/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Jazz Pharmaceuticals Announces Vision 2025 to Deliver Sustainable Growth and Enhanced Value to Drive Transformation to Innovative, Global Biopharmaceutical Leader"
11/09/2021 8-K Quarterly results
Docs: "JAZZ PHARMACEUTICALS ANNOUNCES THIRD QUARTER 2021 FINANCIAL RESULTS AND RAISES FULL YEAR EARNINGS GUIDANCE"
09/23/2021 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
08/03/2021 8-K Quarterly results
Docs: "JAZZ PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS"
07/28/2021 8-K Other Events  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549"
07/01/2021 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549",
"Jazz Pharmaceuticals Announces U.S. FDA Approval of Rylaze ™ -rywn) for the Treatment of Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma"
05/05/2021 8-K Quarterly results
05/04/2021 8-K Quarterly results
04/29/2021 8-K Quarterly results
04/23/2021 8-K Quarterly results
04/22/2021 8-K Quarterly results
04/20/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
03/22/2021 8-K Quarterly results
02/23/2021 8-K Quarterly results
02/03/2021 8-K Quarterly results
02/03/2021 8-K Quarterly results
01/12/2021 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy